Optimal management of patients with fragility fractures and the role of orthopedic surgeons in risk reduction of new fractures;Prise en charge optimale des patients présentant une fracture de fragilité et rôle du chirurgien orthopédiste dans la réduction du risque de nouvelles fractures

Revue de Chirurgie Orthopedique et Reparatrice de l'Appareil Moteur

Volumn 92, Issue 2, 2006, Pages 165-174

  Thomas, T ^a   Feron, J M ^b   Delmas, P D ^c   Kaufman, J ^d   Tosi, L ^e   Cummings, S ^f   Lane, J ^g   Johnell, O ^h   Bouxsein, M L ⁱ  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c UNIVERSITÉ LYON 1   (France)

^d Santa Clarita Orthopedic and Sports Medicine Group   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g HOSPITAL FOR SPECIAL SURGERY   (United States)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

BONE DENSITY; DIAGNOSTIC PROCEDURE; FRAGILITY FRACTURE; HEALTH PROGRAM; HORMONAL THERAPY; HUMAN; LABORATORY TEST; MORBIDITY; MORTALITY; ORTHOPEDIC SURGERY; ORTHOPEDICS; OSTEOPOROSIS; PATIENT ASSESSMENT; RADIOGRAPHY; REVIEW; RISK ASSESSMENT; RISK REDUCTION;

EID: 33646177219     PISSN: 00351040     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-1040(06)75702-6     Document Type: Article

References (50)

1. CUMMINGS SR, MELTON LJ : Epidemiology and outcomes of osteoporotic fractures. Lancet, 2002, 359, 1761-1767.
2. KLOTZBUECHER CM, ROSS PD, LANDSMAN PB, ABBOTT TA III, BERGER M : Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res, 2000, 15, 721-739.
3. FREEDMAN KB, KAPLAN FS, BILKER WB, STROM BL, LOWE RA : Treatment of osteoporosis: Are physicians missing an opportunity? J Bone Joint Surg (Am), 2000, 82, 1063-1070.
4. SIRIS ES, BILEZIKIAN JP, RUBIN MR, BLACK DM, BOCKMAN RS, BONE HG et al. : Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures. J Clin Endocrinol Metab, 2003, 88, 3482-3486.
5. AAOS. Anonymous. Position statement of the American Academy of Orthopaedic Surgeons on recommendations for enhancing the care of patients with fragility fractures. Available at http://www.aaos.org/wordhtml/papers/position/1159.htm. Accessed September 14, 2004.
6. NATIONAL OSTEOPOROSIS FOUNDATION : Physician's guide to the prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2003.
7. MELTON LJ III, CHRISCHILLES EA, COOPER C, LANE AW, RIGGS BL : Perspective: how many women have osteoporosis? J Bone Miner Res, 1992, 7, 1005-1010.
8. CENTER JR, NGUYEN TV, SCHNEIDER D, SAMBROOK PN, EISMAN JA : Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet, 1999, 353, 878-882.
9. BLACK DM, CUMMINGS SR, KARPF DB, CAULEY JA, THOMPSON DE, NEVITT MC et al. : Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: fracture intervention trial research group. Lancet, 1996, 348, 1535-1541.
10. VAN STAA TP, LEUFKENS HG, COOPER C : Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int, 2002, 13, 624-629.
11. BELLANTONIO S, FORTINSKY R, PRESTWOOD K : How well are community-living women treated for osteoporosis after hip fracture? J Am Geriatr Soc, 2001, 49, 1197-1204.
12. DREINHOFER KE, FERON JM, HERRERA A, HUBE R, JOHNELL O, LIDGREN L et al. : Multinational survey of osteoporotic fracture management. Osteoporos Int, 2005 Mar, 16 (suppl. 2), S44-53.
13. CHEVALLEY T, HOFFMEYER P, BONJOUR JP, RIZZOLI R : An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture. Osteoporos Int, 2002, 13, 450-455.
14. MCLELLAN AR, GALLACHER SJ, FRASER M, MCQUILLIAN C : The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int, 2003, 14, 1028-1034.
15. KAUFMAN JD, BOLANDER ME, BUNTA AD, EDWARDS BJ, FITZPATRICK LA, SIMONELLI C : Barriers and solutions to osteoporosis care in patients with a hip fracture. J Bone Joint Surg (Am), 2003, 85, 1837-1843.
16. CUMMINGS SR, BATES D, BLACK DM : Clinical use of bone densitometry: scientific review. JAMA, 2002, 288, 1889-1897.
17. GRISSO JA, KELSEY JL, STROM BL, CHIU GY, MAISLLN G, O'BRIEN LA et al. : Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. N Engl J Med, 1991, 324, 1326-1331.
18. MYERS ER, WILSON SE, GREENSPAN SL : Vertebral fractures in the elderly occur with falling and bending. J Bone Miner Res, 1996, 11 (suppl.), S355.
19. AFSSAPS : Recommandations de bonne pratique pour le traitement médicamenteux de l'ostéoporose post-ménopausique. Disponible en ligne depuis janvier 2006 : http://www.agmed.sante.gouv.fr/pdf/5/rbp/ostemrec.pdf
20. GARNERO P, DELMAS P : Biochemical markers of bone turnover in osteoporosis. In: Marcus R, Kelsey J, Feldman D, (eds): Osteoporosis, ed 2. San Diego, CA: Academic Press, 2001, p. 459-478.
21. KANIS J : Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int, 1994, 4, 368-381.
22. BONNER FJ JR, SINAKI M, GRABOIS M, SHIPP KM, LANE JM, LINDSAY R et al. : Health professional's guide to rehabilitation of the patient with osteoporosis. Osteoporos Int, 2003, 14 (suppl. 2), S1-S22.
23. CHAPUY MC, ARLOT ME, DELMAS PD, MEUNIER PJ : Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ, 1994, 308, 1081-1082.
24. DAWSON-HUGHES B, HARRIS SS, KRALL EA, DALLAL GE : Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med, 1997, 337, 670-676.
25. CRANNEY A, GUYATT G, GRIFFITH L, WELLS G, TUGWELL P, ROSEN C : Meta-analyses of therapies for postmenopausal osteoporosis: IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev, 2002, 23, 570-578.
26. HOCHBERG M : Preventing fractures in postmenopausal women with osteoporosis: A review of recent controlled trials of antiresorptive agents. Drugs Aging, 2000, 17, 317-330.
27. CRANNEY A, GUYATT G, KROLICKI N, WELCH V, GRIFFITH L, ADACHI JD et al. : A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporosis Research Advisory Group (ORAG). Osteoporos Int, 2001, 12, 140-151.
28. HARRIS ST, WATTS NB, GENANT HK, MCKEEVER CD, HANGARTNER T, KELLER M et al. : Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA, 1999, 282, 1344-1352.
29. MCCLUNG MR, GEUSENS P, MILLER PD, ZIPPEL H, BENSEN WG, ROUX C et al. : Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med, 2001, 344, 333-340.
30. ADACHI JD, SAAG KG, DELMAS PD, LIBERMAN UA, EMKEY RD, SEEMAN E et al. : Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum, 2001, 44, 202-211.
31. REID DM, HUGHES RA, LAAN RF, SACCO-GIBSON NA, WENDEROTH DH, ADAMI S et al. : Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-induced Osteoporosis Treatment Study. J Bone Miner Res, 2000, 15, 1006-1013.
32. ORWOLL E, ETTINGER M, WEISS S, MILLER P, KENDLER D, GRAHAM J et al. : Alendronate for the treatment of osteoporosis in men. N Engl J Med, 2000, 343, 604-610.
33. CHESNUT III CH, SKAG A, CHRISTIANSEN C, RECKER R, STAKKESTAD JA, HOISETH A, FELSENBERG D et al. : Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). J Bone Miner Res, 2004, 19, 1241-1249.
34. REID IR, BROWN JP, BURCKHARDT P, HOROWITZ Z, RICHARDSON P, TRECHSEL U et al. : Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med, 2002, 346, 653-661.
35. ROSSOUW JE, ANDERSON GL, PRENTICE RL, LACROIX AZ, KOOPERBERG C, STEFANICK ML et al. : Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288, 321-333.
36. WELLS G, TUGWELL P, SHEA B, GUYATT G, PETERSON J, ZYTARUK N et al. : Meta-analyses of therapies for postmenopausal osteoporosis: V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Endocr Rev, 2002, 23, 529-539.
37. TORGERSON DJ, BELL-SYER SE : Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA, 2001, 285, 2891-2897.
38. Audition publique AFSSAPS-ANAES-INSERM. Les traitements hormonaux substitutifs de la ménopause. Rapport d'orientation 11 mai 2004. Disponible en ligne : http://www.anaes.fr/anaes/Publications.nsf/wEdition/
39. ETTINGER B, BLACK DM, MITLAK BH, KNICKERBOCKER RK, NICKELSEN T, GENANT HK et al. : Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, 1999, 282, 637-645.
40. DELMAS PD, GENANT HK, CRANS GG, STOCK JL, WONG M, SIRIS E et al. : Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab, 2002, 87, 3609-3617.
41. DELMAS PD, GENANT HK, CRANS GG, STOCK JL, WONG M, SIRIS E et al. : Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone, 2003, 33, 522-532.
42. NEER RM, ARNAUD CD, ZANCHETTA JR, PRINCE R, GAICH GA, REGINSTER JY et al. : Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 2001, 344, 1434-1441.
43. MEUNIER PJ, ROUX C, SEEMAN E, ORTOLANI S, BADURSKI JE, SPECTOR TD et al. : The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med, 2004, 350, 459-468.
44. REGINSTER JY, SEEMAN E, DE VERNEJOUL MC, ADAMI S, COMPSTON J, PHENEKOS C et al. : Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endoc Metab, 2005, 90, 2816-2822.
45. GILLESPIE LD, GILLESPIE WJ, ROBERTSON MC, LAMB SE, CUMMING RG, ROWE BH : Interventions for preventing falls in elderly people. Cochrane Database Syst Rev, 2001, 3, CD000340.
46. ROBINOVITCH SN, HAYES WC, MCMAHON TA : Energy-shunting hip padding system attenuates femoral impact force in a simulated fall. J Biomech Eng, 1995, 117, 409-413.
47. PARKER MJ, GILLESPIE LD, GILLESPIE WJ : Hip protectors for preventing hip fractures in the elderly. Cochrane Database Syst Rev, 2001, 2, CD001255.
48. LAURITZEN JB, PETERSEN MM, LUND B : Effect of external hip protectors on hip fractures. Lancet, 1993, 341, 11-13.
49. KANNUS P, PARKKARI J, NIEMI S, PASANEN M, PALVANEN M, JARVINEN M et al. : Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med, 2000, 343, 1506-1513.
50. VAN SCHOOR NM, SMIT JH, TWISK JW, BOUTER LM, LIPS P : Prevention of hip fractures by external hip protectors: a randomized controlled trial. JAMA, 2003, 289, 1957-1962.